Reversibility of Intrathoracic Lipotoxicity in Obesity After Bariatric Surgery Use of Magnetic Resonance Imaging⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. by de Roos, Albert
Journal of the American College of Cardiology Vol. 60, No. 15, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.010EDITORIAL COMMENT
Reversibility of Intrathoracic
Lipotoxicity in Obesity After
Bariatric Surgery
Use of Magnetic Resonance Imaging*
Albert de Roos, MD, PHD
Leiden, the Netherlands
Intrathoracic lipotoxicity is the consequence of increased
accumulation and biological activity of various fat deposits
in obesity, more specifically epicardial (“fat around the
heart”) and intramyocardial fat (“fat within the myocar-
dium”). Epicardial fat is located in close proximity to the
coronary arteries within the visceral pericardial layer (in
contrast to the paracardial or mediastinal fat outside the
pericardial layer). The epicardial fat originates embryologi-
cally from specific mesothelial cells with a vascular supply
from the coronary arteries (1). Epicardial adipose tissue
appears to be biologically active by excreting paracrine and
vasocrine factors that influence local and distant locations.
Bioactive molecules like adiponectin are secreted by the
epicardial fat and are transported to the myocardium and
coronary endothelium through diffusion in the interstitial
fluid and via the vasa vasorum. Adiponectin modulates the
crosstalk between adipose tissue and the vasculature by
inducing nitric oxide production (2). Epicardial fat volume
and adiponectin have been shown to be associated with
coronary vasoreactivity of coronary microcirculation and
coronary atherosclerosis (2).
See page 1381
A large number of alterations mediated by bioactive
molecules and cellular mechanisms (e.g., infiltration of
macrophages) may occur in epicardial fat, contributing to
detrimental effects on cardiac function, coronary vascula-
ture, and pulmonary function (1,3,4). Macrophages play a
central role in promoting the inflammatory response in
adipose tissue in obesity-related disorders. Toxic interme-
diates of lipid metabolism (e.g., ceramide) may activate the
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contents of this paper to disclose.inflammasomes—multiprotein complexes that sense dam-
age—in macrophages, which infiltrate fat deposits, inducing
the transition from obesity to insulin resistance and overt
type 2 diabetes mellitus (5,6). Activated macrophages me-
diate the downregulation of adipocyte apolipoprotein E
expression with site-specific differences for various fat com-
partments in obesity, and thereby, may promote the devel-
opment of coronary artery disease (7). Apolipoprotein E
gene expression is highest in epicardial adipose tissue
compared with other fat deposits like epicardial and visceral
fat, and may have a protective effect against atherosclerosis
(7). Medication may have a differential effect on various fat
compartments in patients with obesity-related disorders.
For example, treatment of patients with type 2 diabetes
mellitus using pioglitazone increases pericardial fat volume,
whereas treatment with metformin does not affect the
amount of pericardial fat (8). Pioglitazone is implicated in
the physiological regulation of adipocyte apolipoprotein E
expression, possibly providing a link between drug action
and site-specific effects (7). Furthermore, epicardial fat may
serve as brown fat to the myocardium by generating heat in
response to cold temperatures and activation of the auto-
nomic nervous system (9).
Intramyocardial fat can also play a role in causing cardiac
dysfunction in obesity-related disorders. This so-called
myocardial lipotoxicity is now recognized as an important
mechanism in heart failure and insulin resistance (10).
Pathological lipid accumulation in the myocardium is evi-
denced by increased levels of toxic lipid intermediates (e.g.,
diacylglycerol and ceramide), which are linked to mitochon-
drial dysfunction, insulin resistance, and apoptosis. Inter-
estingly, mechanical unloading by using ventricular assist
device implantation may reverse the negative effects of
insulin resistance and toxic lipid intermediates in the failing
heart (10). In addition, it has been shown that prolonged
caloric restriction in obese patients with type 2 diabetes
mellitus is associated with decreasing myocardial triglycer-
ides content and improved diastolic function, indicating
that presumed lipotoxicity is reversible and amendable by
metabolic intervention (11).
In particular, the usefulness of magnetic resonance imag-
ing (MRI) and MR proton spectroscopy for assessing fat
accumulation in and around the heart has revived the
recognition of intrathoracic, and more specifically, myocar-
dial lipotoxicity as an important contributing factor in
causing heart failure in obesity-related disorders (12,13).
MRI is well suited to estimate the amount of localized fat
deposits like epicardial, paracardial, and visceral fat. Fur-
thermore, proton MR spectroscopy is uniquely well suited
to probe the amount of intramyocardial triglycerides accu-
mulation noninvasively (14,15). Toxic lipid intermediates
are implicated in insulin resistance, apoptosis, and lipotoxic
cardiomyopathy. It is likely that lipotoxic cardiomyopathy is
highly prevalent in the western population, knowing the
epidemic proportions of obesity-related disorders, but at the
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Lifestyle intervention, medication, and mechanical un-
loading the heart may reverse or prevent lipotoxic car-
diomyopathy. For example, it was shown that pioglitazone
significantly reduces myocardial and hepatic steatosis in
patients with type 2 diabetes mellitus who were treated with
insulin (16).
The study by Gaborit et al. (17) in this issue of the Journal
eports on the effects of bariatric surgery on pericardial fat,
isceral fat, and myocardial triglyceride content assessed by
dvanced MRI technology. As expected, bariatric surgery
ignificantly reduced body mass index (BMI), improved
lycemic control, and decreased subcutaneous fat, visceral
at, and epicardial fat at 6-month follow-up. However, there
as no significant decrease in myocardial triglycerides after
ariatric surgery, although the myocardial triglycerides were
ncreased at baseline. Weight loss was associated with a
ecrease in cardiac output and left ventricular mass and an
mprovement in diastolic heart function in particular. Of
ote, epicardial fat loss was not associated with changes in
MI or visceral fat loss, indicating possible disparate effects
f bariatric surgery on various fat deposits. Patients with
leep apnea syndrome had a lesser decrease in epicardial fat
ompared with those without the syndrome. Furthermore,
he type of surgery did not appear to result in differences in
eight loss or epicardial fat loss, although only 25 patients
ere included (19 sleeve gastrectomies, 5 Roux-en-Y gastric
ypass operations, and 1 adjustable gastric banding). This
tudy highlights the disparate biological responses of various
ctopic fat deposits and cardiovascular function after bari-
tric surgery (17). The differential changes in epicardial fat
oss after bariatric surgery and the suggested relationship
ith the sleep apnea syndrome seem to indicate a deposit-
pecific biological effect. In line with a possible disparate
ffect on various fat deposits, previous studies showed a
ong-term beneficial and sustained effect on pericardial fat
oss with diet intervention in obese, type 2 diabetes mellitus
atients, despite weight regain at long-term follow-up (18).
The lack of a decrease in myocardial triglycerides after
ariatric surgery reported in this study is somewhat puz-
ling, because cardiovascular function improved, indicating
biological effect to the myocardium. Underpowering of the
tudy may possibly account for the lack of demonstrating a
ecrease of myocardial triglycerides in conjunction with an
mprovement in diastolic left ventricular function. In con-
rast, it has been suggested that a decrease in myocardial
riglycerides may not be a prerequisite for improved
entricular function after metabolic intervention (3). Over-
ll, the study of Gaborit et al. (17) illustrates the strength
nd utility of noninvasive MRI tools for probing multiple
at deposits and cardiovascular function in a single exami-
ation for evaluating the effects of metabolic and/or bariat-
ic surgery in obesity.
In general, MRI and spectroscopy have great potential to
valuate multiple relevant imaging biomarkers to assess the
ardiovascular risk in obesity and obesity-related disorders(19). Proton spectroscopy is the most accurate noninvasive
method to estimate liver fat, which is strongly related to
insulin resistance, atherogenic dyslipidemia, and higher
circulating inflammatory biomarkers (19). Furthermore,
obesity and the metabolic syndrome are associated with
accelerated arterial aging and increased arterial stiffness,
which can be estimated as pulse-wave velocity and aortic
distensibility with the aid of MRI (19). For example, local
aortic stiffness measured by MRI is independently associ-
ated with systolic left ventricular function, cerebral white
matter disease, and renal function in diabetic patients,
illustrating the systemic nature of diabetes involving multi-
ple organs (20–22). Interestingly, obesity-related disorders
are related to cerebral atrophy, white matter lesions, and
brain infarctions that may contribute to early cognitive
decline and dementia (23). In addition to the measurement
of increased accumulation of epicardial and intramyocardial
fat, MRI offers great versatility to define multiple other
cardiovascular risk factors, such as small, silent myocardial
infarction, the ischemic cascade culminating in overt myo-
cardial infarction, and diffuse myocardial fibrosis in patients
with obesity-related disorders (19,24). Moreover, phospho-
rus 31 MR spectroscopy of the liver may be helpful to probe
intermediates of membrane metabolism that signal the
transition from uncomplicated liver steatosis to steatohepa-
titis (nonalcoholic steatohepatitis) (19).
In conclusion, bariatric surgery has a substantial effect on
weight loss, but the mechanism of action is poorly under-
stood (25). In particular, the nonweight loss effect of
bariatric surgery has raised interest in the surgical option as
a treatment for subjects with type 2 diabetes mellitus. It is
evident that the versatility of MRI techniques for multior-
gan imaging may be well suited to define selection criteria,
establish mechanisms of surgical intervention, and assess
long-term multiorgan effects after metabolic and/or bariatric
intervention.
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